Related references
Note: Only part of the references are listed.HLA-DRB1*15 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis
Kerstin Imrell et al.
JOURNAL OF NEUROIMMUNOLOGY (2009)
CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients
F. G. Joseph et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2009)
HLA-DRBI*0401 and HLA-DRBI*0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis
Steve Hoffmann et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Using measurements of neutralizing antibodies:: the challenge of IFN-β therapy
D. Hesse et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta
A. Bertolotto et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity
A. Sominanda et al.
MULTIPLE SCLEROSIS (2007)
Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct
Kerstin Imrell et al.
NEUROLOGY (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
HILA-related subpopulations of MS in Japanese with and without oligoclonal IgG bands
S Kikuchi et al.
NEUROLOGY (2003)
Share Paper
